The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
01 01 2023
01 01 2023
Historique:
received:
25
11
2021
pubmed:
22
4
2022
medline:
4
1
2023
entrez:
21
4
2022
Statut:
epublish
Résumé
Somatic mutations are recognized as an important prognostic factor in chronic myelomonocytic leukemia (CMML). However, limited data are available regarding their impact on outcomes after allogeneic hematopoietic cell transplantation (HCT). In this registry analysis conducted in collaboration with the Center for International Blood and Marrow Transplantation Registry database/sample repository, we identified 313 adult patients with CMML (median age: 64 years, range, 28- 77) who underwent allogeneic HCT during 2001-2017 and had an available biospecimen in the form of a peripheral blood sample obtained prior to the start of conditioning. In multivariate analysis, a CMML-specific prognostic scoring system (CPSS) score of intermediate-2 (HR=1.46, P=0.049) or high (HR=3.22, P=0.0004) correlated significantly with overall survival. When the molecularly informed CPSS-Mol prognostic model was applied, a high CPSS-Mol score (HR=2 P=0.0079) correlated significantly with overall survival. The most common somatic mutations were in ASXL1 (62%), TET2 (35%), KRAS/NRAS (33% combined), and SRSF2 (31%). DNMT3A and TP53 mutations were associated with decreased overall survival (HR=1.70 [95% CI: 1.11-2.60], P=0.0147 and HR=2.72 [95% CI: 1.37-5.39], P=0.0042, respectively) while DNMT3A, JAK2, and TP53 mutations were associated with decreased disease-free survival (HR=1.66 [95% CI: 1.11-2.49], P=0.0138, HR=1.79 [95% CI: 1.06-3.03], P=0.0293, and HR=2.94 [95% CI: 1.50-5.79], P=0.0018, respectively). The only mutation associated with increased relapse was TP53 (HR=2.94, P=0.0201). Nonetheless, the impact of TP53 mutations specifically should be interpreted cautiously given their rarity in CMML. We calculated the goodness of fit measured by Harrell's C-index for both the CPSS and CPSS-Mol, which were very similar. In summary, via registry data we have determined the mutational landscape in patients with CMML who underwent allogeneic HCT, and demonstrated an association between CPSS-Mol and transplant outcomes although without major improvement in the risk prediction beyond that provided by the CPSS.
Identifiants
pubmed: 35443559
doi: 10.3324/haematol.2021.280203
pmc: PMC9827167
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
150-160Subventions
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Leuk Lymphoma. 2004 Jul;45(7):1311-8
pubmed: 15359628
Br J Haematol. 2002 Jul;118(1):67-73
pubmed: 12100129
JAMA. 1982 May 14;247(18):2543-6
pubmed: 7069920
Nat Commun. 2016 Feb 24;7:10767
pubmed: 26908133
Blood Cancer J. 2020 Nov 20;10(11):121
pubmed: 33219206
Blood Adv. 2020 Sep 22;4(18):4362-4365
pubmed: 32926123
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Biol Blood Marrow Transplant. 2011 Jun;17(6):908-15
pubmed: 20932924
Leukemia. 2013 Jul;27(7):1504-10
pubmed: 23531518
Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S1-S2
pubmed: 18724277
Br J Haematol. 2016 Aug;174(3):382-96
pubmed: 27061824
Am J Hematol. 2014 Dec;89(12):1111-5
pubmed: 25195656
Am J Hematol. 2020 Jan;95(1):97-115
pubmed: 31736132
Haematologica. 2019 Oct;104(10):1935-1949
pubmed: 31048353
Blood. 2011 Oct 6;118(14):3824-31
pubmed: 21828134
Br J Haematol. 2015 Oct;171(2):239-246
pubmed: 26212516
Blood. 2012 Mar 15;119(11):2657-64
pubmed: 22234678
Bone Marrow Transplant. 2009 Apr;43(8):659-61
pubmed: 18997830
Leukemia. 2017 Dec;31(12):2815-2823
pubmed: 28555081
Biol Blood Marrow Transplant. 2005 Sep;11(9):713-20
pubmed: 16125642
Blood Adv. 2021 Mar 23;5(6):1760-1769
pubmed: 33755092
Blood. 2013 Apr 11;121(15):3005-15
pubmed: 23372164
J Clin Oncol. 2013 Jul 1;31(19):2428-36
pubmed: 23690417
Blood. 2016 Sep 8;128(10):1408-17
pubmed: 27385790
Biol Blood Marrow Transplant. 2017 May;23(5):767-775
pubmed: 28115276
Bone Marrow Transplant. 2006 Jun;37(11):1003-8
pubmed: 16604096
Blood Cancer J. 2016 Feb 05;6:e393
pubmed: 26849014
J Clin Oncol. 2016 Oct 20;34(30):3627-3637
pubmed: 27601546
Leuk Res. 2008 Apr;32(4):587-91
pubmed: 17881052
Eur J Haematol. 2013 May;90(5):355-64
pubmed: 23320648
Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151
pubmed: 30625392
Haematologica. 2020 Mar;105(3):652-660
pubmed: 31289199
Blood. 2016 Nov 17;128(20):2381-2387
pubmed: 27707735
Blood. 2008 Jul 1;112(1):45-52
pubmed: 18443215
Cancer. 2007 Feb 15;109(4):713-7
pubmed: 17219444
Biostatistics. 2014 Jul;15(3):526-39
pubmed: 24493091
Curr Hematol Malig Rep. 2021 Jun;16(3):247-255
pubmed: 33660195
Blood Adv. 2020 Aug 25;4(16):3864-3874
pubmed: 32810221